MONTREAL, CANADA -- (Marketwire) -- 03/14/13 -- MethylGene Inc. ("MethylGene" or the "Company") (TSX: MYG) today announced that Messrs. Jeffrey M. Besterman, PhD, Executive Vice President Research and Development and Chief Scientific Officer, Joe Walewicz, Vice President of Business and Corporate Development and Klaus B. Kepper, Vice President Finance and Chief Financial Officer, will be leaving the company to pursue other interests.
Effective immediately, the responsibilities of Dr. Besterman have been assumed by Charles Baum, MD PhD, CEO, and the responsibilities of Mr. Kepper and Mr. Walewicz have been assumed by Mark Gergen, COO. Each of the executives will depart following a brief transition period.
"I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene" said Dr. Charles Baum, President and CEO, "we wish them the best in their future pursuits".
MethylGene Inc. (TSX: MYG) is a drug development company that is advancing novel therapeutics for cancer and infectious disease in human clinical trials. The Company's lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is in a Phase II trial for vulvovaginal candidiasis, and MGCD265, a multi-targeted receptor tyrosine kinase inhibitor that is in Phase I/II clinical trials for patients with solid tumors. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of MethylGene and upon what management believes to be reasonable assumptions, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. Such statements can usually be identified by the use of words such as "may", "would", "believe", "plan", "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would"be taken, occur or be acheived These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations;the results of clinical trials; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD265, MGCD290 or our other programs; the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD265, MGCD290 or our other products, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD265 or MGCD290. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, as described in MethylGene's Annual Information Form under the heading "Risk Factors" which you are urged to read, and all other documents filed by the Company that can be found at www.sedar.com. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this news release. These statements speak only as of the date they are made and MethylGene expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in MethylGene's expectations with regard thereto of any change in events, conditions or circumstances on which any such statements are based except in accordance with law.
Investor Relations Contact:
Mark J. Gergen
Executive Vice President & COO
email@example.com / www.methylgene.com
The Trout Group LLC
Most Popular Stories
- Americans Still Pessimistic Despite Economic Growth
- Apple to Unveil New Items on Sept. 9
- Friends Followed Similar Paths to Violent Jihad
- Axxis Solutions Appoints Benites as CEO
- Parra Joins Exclusive Club of Hispanic CEOs
- Obama Puts Ukraine Violence on Russia
- California Moves Toward Ban on Plastic Bags
- Identity Thieves Prey on Job Seekers
- Hillary Clinton Breaks Silence on Ferguson
- Janet Yellen's Assets Grew by 8 Percent in 2013